Clinical observation of atomization inhalation of budesonide and formoterol plus salbutamol for asthma treatment in infants
AIM: To investigate the clinical efficacy of atomization inhalation of budesonide (BUD) and formoterol (FOM) plus salbutamol (SAB) in the treatment of asthma in infants. METHODS: From January 2006 to December 2007, 130 infants diagnosed with mild to severe persistent asthma were randomly divided into 3 groups: Respules group (inhaling BUD and FOM plus SAB suspension by jet nebulizatianal machine with facial mask), MDI group ( inhaling BUD and FOM plus SAB metered dose inhaler by spacer with facial mask) and Control group ( inhaling no corticesteroids). Efficacy was assessed by receding nighttime and daytime symptom scores, the percentage of symptom-free days, the times of worsening asthma, requirement for oral corticosteroids and the daily beta2-receptor agonist used on a daily diary card. The data needed were recorded respectively on the 4th week, 12th week, 24th week and 48th week. RESULTS: Better effects were observed in both Resplues group and MDI group in reducing nighttime and daytime symptom scores, diminishing the exacerbations of asthma, decreasing the need for beta2-receptor agonists and oral corticosteruids, and increasing the percentage of symptom-free days, compared with those in control group ( P <0.01 ). Significantly better effect was found by 4th week and 12th week in the Respules group compared with that in MDI group (P < 0. 05 ), while no significant difference was found between the two groups by 24th week and 48th week. CONCLUSION: The results of tiffs study demonstrate that the inhalation of budesonide and formoterol plus salbutamol suspension by jet nebulization effectively alleviates the symptoms of asthma and achieves longterm stabilization, which is the first choice in the treatment of asthma in infants.
NETL
NSTL
万方数据
维普
